Valneva SE VALN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Valneva SE (VALN) is a healthcare company listed in the US with a market value of about $537M. In the twelve months to June 30, 2026 it had revenue of $158M and net income of -$174M, a net margin of -110.3%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 9% a year, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Valneva
Valneva is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $142M in 2019 to $205M in 2025, growth of about 6.4% a year. It was profitable in 0 of the last 7 years in our data.
Score: 0.4 / 5
Checks passed
- Revenue growth above 10% last year
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $158M | $205M | $176M | $170M | $385M | $394M | $135M | $142M |
| Net income | -$174M | -$135M | -$13M | -$112M | -$153M | -$70M | -$68M | -$911082 |
| Free cash flow | -$64M | -$67M | -$84M | -$240M | -$293M | -$17M | $146M | -$6M |
| EPS (diluted) | $-1.95 | $-1.43 | $-0.13 | $-1.18 | $-1.61 | $-0.73 | $-0.71 | $-0.01 |
| Net margin | -110.3% | -66.0% | -7.2% | -66.0% | -39.7% | -17.6% | -50.0% | -0.6% |
| ROIC | — | -22.7% | 2.9% | -21.3% | -35.2% | -21.2% | -41.6% | -0.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Valneva stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Valneva pay a dividend?
Not currently.
Is Valneva a good stock to buy?
We do not give buy or sell advice. Valneva scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.